Form 4: TScan Therapeutics Director Gabriela Gruia Granted 67,000 Stock Options

TScan Therapeutics, Inc. Director Gabriela Gruia was granted 67,000 stock options with an exercise price of $1.45, vesting upon the earlier of June 30, 2026, or the next annual stockholders' meeting.

Summary

• Director Gabriela Gruia of TScan Therapeutics, Inc. (TCRX) was granted 67,000 stock options.
• The options have an exercise price of $1.45 per share.
• The transaction date for this grant was June 30, 2025.
• The options will vest and become exercisable in full upon the earlier of June 30, 2026, or the next annual meeting of the Issuer's stockholders, contingent on Ms. Gruia's continued service.
• The options expire on June 30, 2035.
• Following this transaction, Ms. Gruia beneficially owns 67,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The document reports a standard equity grant to a director, which is a neutral to slightly positive event as it aligns director interests with shareholders. It does not contain significant positive or negative financial news.

Positives

• Granting of stock options to a director aligns their interests with shareholders, incentivizing long-term performance.
• The options have a 10-year expiration date, providing a long window for potential value realization.

Negatives

• No immediate cash benefit to the director from the grant itself, as it is an option, not a direct share award.
• The value of the options is contingent on the future stock price exceeding the exercise price of $1.45.

Future Outlook

The 67,000 stock options granted to Director Gabriela Gruia are set to vest upon the earlier of June 30, 2026, or the next annual meeting of the Issuer's stockholders, provided her continued service. This structure ties future compensation to continued tenure and potential stock price appreciation.

Industry Context

Stock option grants are a common form of equity compensation for directors and executives in the biotechnology and pharmaceutical industries, like TScan Therapeutics, to align their interests with long-term shareholder value creation and retain talent.

Comparison to Industry Standards

• The grant of 67,000 stock options to a director is a standard practice for incentivizing leadership in biotech companies, comparable to equity compensation packages seen at similar-stage biopharmaceutical firms.
• An exercise price of $1.45, which is likely the closing price on the grant date, is typical for at-the-money option grants.
• A 10-year expiration period (until June 30, 2035) is a common duration for employee and director stock options in the industry, providing a long-term incentive horizon.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their incentives with shareholder interests, potentially encouraging decisions that enhance long-term stock value.

Next Steps

• The stock options will vest upon the earlier of June 30, 2026, or the next annual meeting of TScan Therapeutics' stockholders, subject to Gabriela Gruia's continued service.

Key Dates

Keywords

TScan Therapeutics, TCRX, Stock Option Grant, Director Compensation, SEC Form 4, Insider Transaction, Equity Compensation, Gabriela Gruia